NUMB endocytic adaptor protein (NUMB) mediates the anti-hepatic fibrosis effect of artesunate (ART) by inducing senescence in hepatic stellate cells (HSCs)

Abstract

Developing and identifying effective medications and targets for treating hepatic fibrosis is an urgent priority. Our previous research demonstrated the efficacy of artesunate (ART) in alleviating liver fibrosis by eliminating activated hepatic stellate cells (HSCs). However, the underlying mechanism remains unclear despite these findings. Notably, endocytic adaptor protein (NUMB) has significant implications for treating hepatic diseases, but current research primarily focuses on liver regeneration and hepatocellular carcinoma. The precise function of NUMB in liver fibrosis, particularly its ability to regulate HSCs, requires further investigation. This study aims to elucidate the role of NUMB in the anti-hepatic fibrosis action of ART in HSCs. We observed that the expression level of NUMB significantly decreased in activated HSCs compared to quiescent HSCs, exhibiting a negative correlation with the progression of liver fibrosis. Additionally, ART induced senescence in activated HSCs through the NUMB/P53 tumor suppressor (P53) axis. We identified NUMB as a crucial regulator of senescence in activated HSCs and as a mediator of ART in determining cell fate. This research examines the specific target of ART in eliminating activated HSCs, providing both theoretical and experimental evidence for the treatment of liver fibrosis.

Keywords

Hepatic stellate cells / NUMB endocytic adaptor protein / Senescence / Artesunate / Ubiquitylation / Liver fibrosis

References

[1] Li N, Zhang X, Zhou J, et al. Multiscale biomechanics and mechanotransduction from liver fibrosis to cancer. Adv Drug Deliver Rev. 2022;188:114448. https://doi.org/10.1016/j.addr.2022.114448.

[2] Yang X, Li Q, Liu W, et al. Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment. Cell Mol Immunol. 2023; 20(6):583-599. https://doi.org/10.1038/s41423-023-00983-5.

[3] Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastro Hepat. 2017; 14(7):397-411. https://doi.org/10.1038/nrgastro.2017.38.

[4] Du K, Maeso-Diaz R, Oh SH, et al. Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis. Hepatology. 2023; 77(6):1998-2015. https://doi.org/10.1097/HEP.0000000000000326.

[5] Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliver Rev. 2017; 121:27-42. https://doi.org/10.1016/j.addr.2017.05.007.

[6] Wang F, Li Z, Chen L, et al. Inhibition of ASCT2 induces hepatic stellate cell senescence with modified proinflammatory secretome through an IL-1α/NF-kappaB feedback pathway to inhibit liver fibrosis. Acta Pharm Sin B. 2022; 12(9):3618-3638. https://doi.org/10.1016/j.apsb.2022.03.014.

[7] Miwa S, Kashyap S, Chini E, et al. Mitochondrial dysfunction in cell senescence and aging. J Clin Invest. 2022; 132(13):e158447. https://doi.org/10.1172/JCI158447.

[8] Wang Y, Li Y, Qiu Y, et al. Artesunate induces ferroptosis in hepatic stellate cells and alleviates liver fibrosis via the ROCK1/ATF3 axis. J Clin Transl Hepato. 2024; 12(1):36-51. https://doi.org/10.14218/JCTH.2023.00162.

[9] Huang Z, Gan S, Zhuang X, et al. Artesunate inhibits the cell growth in colorectal cancer by promoting ROS-dependent cell senescence and autophagy. Cells. 2022; 11(16):2472. https://doi.org/10.3390/cells11162472.

[10] Wu D, Prives C. Relevance of the p53-MDM2 axis to aging. Cell Death Differ. 2018; 25(1):169-179. https://doi.org/10.1038/cdd.2017.187.

[11] Aubrey BJ, Kelly GL, Janic A, et al. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018; 25(1):104-113. https://doi.org/10.1038/cdd.2017.169.

[12] Ou HL, Schumacher B. DNA damage responses and p53 in the aging process. Blood. 2018; 131(5):488-495. https://doi.org/10.1182/blood-2017-07-746396.

[13] Wei S, Liu L, Chen Z, et al. Artesunate inhibits the mevalonate pathway and promotes glioma cell senescence. J Cell Mol Med. 2020; 24(1):276-284. https://doi.org/10.1111/jcmm.14717.

[14] Wang H, Guo M, Wei H, et al. Targeting p 53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Tar. 2023; 8(1):92. https://doi.org/10.1038/s41392-023-01347-1.

[15] Li H, Shu S, Zhou M, et al. NUMB facilitates autophagy initiation through targeting SCF^β-TrCP2 complex. Cell Death Differ. 2022; 29(7):1409-1422. https://doi.org/10.1038/s41418-022-00930-3.

[16] Belle VA, McDermott N, Meunier A, et al. NUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer. Nat Rev Urol. 2014; 11(9):499-507. https://doi.org/10.1038/nrurol.2014.195.

[17] Wu MJ, Chen YS, Kim MR, et al. Epithelial-mesenchymal transition directs stem cell polarity via regulation of mitofusin. Cell Metab. 2019; 29(4):993-1002, e1006. https://doi.org/10.1016/j.cmet.2018.11.004.

[18] Conboy IM, Conboy MJ, Smythe GM, et al. Notch-mediated restoration of regenerative potential to aged muscle. Science. 2003; 302(5650):1575-1577. https://doi.org/10.1126/science.1087573.

[19] Le Roux I, Konge J, Le Cam L, et al. Numb is required to prevent p53-dependent senescence following skeletal muscle injury. Nat Commun. 2015;6:8528. https://doi.org/10.1038/ncomms9528.

[20] Carter S, Vousden KH. A role for Numb in p53 stabilization. Genome Biol. 2008; 9(5):221. https://doi.org/10.1186/gb-2008-9-5-221.

[21] Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature. 2008; 451(7174):76-80. https://doi.org/10.1038/nature06412.

[22] Shen M, Li Y, Wang Y, et al. N⁶-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells. Redox Biol. 2021;47:102151. https://doi.org/10.1016/j.redox.2021.102151.

[23] Forli S, Huey R, Pique ME, et al. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc. 2016; 11(5):905-919. https://doi.org/10.1038/nprot.2016.051.

[24] Tung EK, Mak CK, Fatima S, et al. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int. 2011; 31(10):1494-1504. https://doi.org/10.1111/j.1478-3231.2011.02597.x.

[25] Rho H, Terry AR, Chronis C, et al. Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis. Cell Metab. 2023; 35(8):1406-1423, e1408. https://doi.org/10.1016/j.cmet.2023.06.013.

[26] Sufletel RT, Melincovici CS, Gheban BA, et al. Hepatic stellate cells - from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology. Rom J Morphol Embryol. 2020; 61(3):615-642. https://doi.org/10.47162/RJME.61.3.01.

[27] Lanz MC, Zatulovskiy E, Swaffer MP, et al. Increasing cell size remodels the proteome and promotes senescence. Mol Cell. 202;82(17):3255-3269, e3258. https://doi.org/10.1016/j.molcel.2022.07.017.

[28] Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008; 134(4):657-667. https://doi.org/10.1016/j.cell.2008.06.049.

[29] Hernandez-Segura A, Nehme J, Demaria M.Hallmarks of cellular senescence. Trends Cell Biol. 2018; 28(6):436-453. https://doi.org/10.1016/j.tcb.2018.02.001.

[30] Martinez-Alonso D, Malumbres M.Mammalian cell cycle cyclins. Semin Cell Dev Biol. 2020; 107:28-35. https://doi.org/10.1016/j.semcdb.2020.03.009.

[31] Li MR, Lei CT, Tang H, et al. MAD2B promotes podocyte injury through regulating Numb-dependent Notch 1 pathway in diabetic nephropathy. Int J Biol Sci. 2022; 18(5):1896-1911. https://doi.org/10.7150/ijbs.68977.

[32] Hristova DM, Fukumoto T, Takemori C, et al. NUMB as a therapeutic target for melanoma. J Invest Dermatol. 2022; 142(7):1882-1892,e1885. https://doi.org/10.1016/j.jid.2021.11.027.

[33] Lacomme M, Hales SC, Brown TW, et al. Numb regulates Tau levels and prevents neurodegeneration in tauopathy mouse models. Sci Adv. 2022; 8(42):eabm4295. https://doi.org/10.1126/sciadv.abm4295.

[34] Schinagl M, Tomin T, Gindlhuber J, et al. Proteomic changes of activated hepatic stellate cells. Int J Mol Sci. 2021; 22(23):12782. https://doi.org/10.3390/ijms222312782.

[35] Hahn F, Niesar A, Wangen C, et al. Target verification of artesunate-related antiviral drugs: assessing the role of mitochondrial and regulatory proteins by click chemistry and fluorescence labeling. Antivir Res. 2020;180:104861. https://doi.org/10.1016/j.antiviral.2020.104861.

[36] Yuan J, Luo K, Zhang L, et al. USP 10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010; 140(3):384-396. https://doi.org/10.1016/j.cell.2009.12.032.

[37] Qin X, Cao Y. Prognostic biomarker NUMB is inhibited by breast cancer cell exosomes to promote breast cancer progression. J Immunol Res. 2022;2022:6032076. https://doi.org/10.1155/2022/6032076.

[38] Shu Y, Xu Q, Xu Y, et al. Loss of Numb promotes hepatic progenitor expansion and intrahepatic cholangiocarcinoma by enhancing Notch signaling. Cell Death Dis. 2021; 12(11):966. https://doi.org/10.1038/s41419-021-04263-w.

[39] Ortega-Campos SM, Garcia-Heredia JM. The multitasker protein: a look at the multiple capabilities of NUMB. Cells. 2023; 12(2):333. https://doi.org/10.3390/cells12020333.

[40] Dhami GK, Liu H, Galka M, et al. Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis. Mol Cell. 2013; 50(4):565-576. https://doi.org/10.1016/j.molcel.2013.04.028.